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Background. Infection is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). 
Our object was to better define the epidemiology and outcomes of infections after HCT.
Methods. This was a prospective, multicenter cohort study of HCT recipients and conducted from 2006 to 2011. The study 
included 4 US transplant centers and 444 HCT recipients. Data were prospectively collected for up to 30 months after HCT using a 
standardized data collection tool.
Results. The median age was 53 years, and median follow up was 413 (range, 5–980) days. The most common reason for HCT 
was hematologic malignancy (87%). The overall crude mortality was 52%. Death was due to underlying disease in 44% cases and 
infection in 21%. Bacteremia occurred in 231 (52%) cases and occurred early posttransplant (median day 48). Gram-negative 
bloodstream infections were less frequent than Gram-positive, but it was associated with higher mortality (45% vs 13%, P = .02). 
Clostridium difficile infection developed in 148 patients (33%) at a median of 27 days post-HCT. There were 53 invasive fungal infec-
tions (IFIs) among 48 patients (11%). The median time to IFI was 142 days. Of 155 patients with cytomegalovirus (CMV) infection, 
4% had CMV organ involvement. Varicella zoster infection (VZV) occurred in 13 (4%) cases and was disseminated in 2. Infection 
with respiratory viruses was seen in 49 patients. Pneumocystis jirovecii pneumonia was rare (1%), and there were no documented 
cases of nocardiosis, toxoplasmosis, endemic mycoses, or mycobacterial infection. This study lacked standardized antifungal and 
antiviral prophylactic strategies.
Conclusions. Infection remains a significant cause of morbidity and mortality after HCT. Bacteremias and C difficile infection 
are frequent, particularly in the early posttransplant period. The rate of IFI is approximately 10%. Organ involvement with CMV is 
infrequent, as are serious infections with VZV and herpes simplex virus, likely reflecting improved prevention strategies.
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More than 8000 allogeneic hematopoietic cell transplants 
(HCTs) are performed annually in North America. Significant 
strides have been made in the last few decades to decrease 
the incidence of serious infections, such as those due to cyto-
megalovirus (CMV) and varicella zoster virus (VZV), but infec-
tion remains a leading cause of morbidity and mortality after 
HCT [1–5]. The types of patients receiving HCT, as well as the 
conditioning regimen used, and the source of stem cells and 
immunosuppressive regimens used, differ across institutions 
and have changed over time. Prospectively collected data from 
multiple, geographically diverse centers are vital to the under-
standing of infectious complications and to the development of 
prophylactic and treatment strategies. No multicenter studies 
have prospectively evaluated the epidemiology, risk factors, 
and outcomes of all infectious complications after HCT. Most 
studies have been from single institutions or have focused on 
specific types of infections [1–4, 6–9]. We created the Organ 
Transplant Infection Project (OTIP), a network of 6 collabo-
rating transplant centers, in 2006 to prospectively collect data 
on all infectious complications and to investigate a variety of 
potential risk factors and outcomes in a cohort of all allogen-
eic HCT recipients and lung transplant recipients over a 5-year 
period. This report examines the HCT population only.
METHODS
The OTIP is a network of 6 collaborating transplant centers 
(University of Pennsylvania, University of Michigan, 
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Washington University in St. Louis, Cleveland Clinic, University 
of Pittsburgh, University of Alabama at Birmingham), in collab-
oration with the Centers for Disease Control and Prevention 
(CDC). Four centers (University of Michigan, University 
of Alabama, University of Pennsylvania, and Washington 
University) contributed patients undergoing HCT to the cur-
rent study. Data were prospectively collected from each of the 
centers during 2006–2011. All sites received local institutional 
review board approval before patient enrollment. Patients were 
followed for up to 30 months posttransplant. Study visits were 
performed weekly for the first 4 months and during inpatient 
stays, and monthly thereafter.
All patients ≥18 years of age who underwent allogeneic HCT 
at the 4 sites were eligible for enrollment. Data collected at 
enrollment included demographic information, details about 
the transplant donor type (related or unrelated), graft source 
(bone marrow, peripheral stem cells, or umbilical cord stem 
cells), human leukocyte antigen match, conditioning regimen, 
and immunosuppression as well as recipient comorbidities.
Use of antifungal and antiviral prophylaxis and empiric ther-
apy for neutropenic fever was at the discretion of each center. 
Antifungal prophylaxis was defined as follows: the use of a sys-
temic antifungal agent for at least 7 days in the absence of a sus-
pected or confirmed invasive fungal infection (IFI). Antiviral 
prophylaxis was defined as use of an antiviral agent for at least 
7 days in the absence of a suspected or confirmed viral infection. 
Infectious syndromes were defined using Modified National 
Nosocomial Infection Surveillance System (restructured in 2005 
to become National Healthcare Safety Network) definitions [10].
Suspected infections other than CMV or IFI were defined as 
any clinical syndrome for which antimicrobial treatment was 
initiated. Cytomegalovirus infection was defined as detection 
of CMV in the blood by polymerase chain reaction or pp65 
antigenemia testing, positive histopathology, or a positive CMV 
immunostain on a tissue biopsy. Infection onset date was con-
sidered to be the date of the first diagnostic culture or test, or 
if the diagnosis date was unknown, the symptom onset date. 
An infection was considered new if it occurred at least 2 weeks 
after the resolution of a previous episode. Invasive fungal infec-
tions were defined according to the European Organization 
for Research and Treatment of Cancer/Mycoses Study Group 
(EORTC/MSG) criteria [11]. An adjudication committee, con-
sisting of 5 study investigators, reviewed each reported IFI and 
included only those that were proven or probable by the 2008 
EORTC/MSG criteria [11].
Statistical Methods
Data collected by the OTIP centers were transmitted to the 
CDC via an electronic case report form. Categorical variables 
were analyzed using χ2 tests or Fisher’s exact tests, as appro-
priate. In all analyses, a 2-tailed level of significance was set to 
α = 0.05. All analyses were done using SAS 9.3 (SAS Institute, 
Inc., Cary, NC).
Role of the Funding Source
The CDC developed the data collection tool and served as the 
central unit for data processing and analysis.
RESULTS
During 2006–2011, we enrolled 444 allogeneic HCTs among 
431 patients at 4 US transplant centers (153 from University of 
Michigan Healthcare System, 24 from University of Alabama, 
60 from University of Pennsylvania, and 207 from Washington 
University); 431 patients had 1 transplant, 12 patients had 2 
transplants, and 1 patient had 3 transplants. This represents 48% 
of all patients who recieved transplants during the enrollment 
period. Enrollment rates across the 4 different centers ranged 
from 32% to 57%. The median age was 53 years (range, 18–75), 
and the median duration of follow up was 413  days (range, 
5–980) (Table 1). The most common indication for HCT was 
hematologic malignancy (87%). Most of the transplants were 
from matched, unrelated donors (55%) or from matched, 
related donors (40%) (Table 2). The conditioning regimen was 
myeloablative in 72%, and the source of hematopoietic cells was 
peripheral blood in 87%. Relapsed malignancy was present at 
the time of HCT in 113 (26%) of patients. The median time to 
engraftment was 12 days (0–101).
Immunosuppression and Antimicrobial Prophylaxis
Most patients received tacrolimus for immunosuppression. 
Graft-versus-host disease (GVHD) developed in 339 (76%) 
Table 1. Organ Transplant Infection Project (2006–2011): Characteristics 
of 444 Hematopoietic Cell Transplant Patientsa
Characteristic n (Percent or Range)
Total cases 444 (100)
Median age, years 53 (18–75)
Male sex 256 (58)
White race 421 (95)
Median days of follow up 413 (5–980)
Indication for Transplant
Hematologic malignancy 387 (87)
 Acute myelogenous leukemia 180 (41)
 Non-Hodgkins lymphoma  79 (18)
 Acute lymphocytic leukemia 41 (9)
 Chronic myelogenous leukemia 24 (5)
 Hodgkin’s disease  9 (2)
Other hematologic disease 57 (13)
 Myelodysplastic syndrome 41 (9)
 Other indications 16 (3)
Comorbidities
 Cardiovascular disease 112 (25)
 Type 1 diabetes 31 (7)
 Type 2 diabetes 20 (5)
 Pulmonary disease 29 (7)
 Splenectomy 7 (2)
 Chronic kidney disease 5 (1)
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patients. Use of antiviral prophylaxis at some point after HCT 
was as follows: acyclovir (70%), valacyclovir (40%), valganci-
clovir (4%), and ganciclovir (1%). Antifungal prophylaxis was 
used in 368 patients (83%). Medications used as antifungal 
prophylaxis during the posttransplant period included the fol-
lowing: fluconazole (53%), voriconazole (35%), caspofungin 
(5%), posaconazole (3%), amphotericin B (<1%), and itracona-
zole (<1%). Trimethoprim-sulfamethoxazole (59%), dapsone 
(29%), and atovaquone (7%) were used for prophylaxis against 
Pneumocystis jiroveci.
Syndromes and Bacterial Infections
Infection occurred in 415 (93%) of transplants. Bloodstream 
infections were the most common site, occurring in 231 (56%) 
of 410 patients who had an infection (56%). Median time to 
first bloodstream infection was 48 days (0–847). Bacteremias 
were caused by Gram-positive bacteria in 244 (56%), Gram-
negative bacteria in 93 (21%), and were polymicrobial in 50 
(12%). The majority of Gram-positive bacteremias were caused 
by coagulase-negative staphylococci and enterococci (Table 3). 
Pseudomonas aeruginosa was the most frequent cause of Gram-
negative bacteremia (26%) (Table 3). Anaerobic bloodstream 
infections were rare, with only 1 case of Bacteroides fragilis bac-
teremia reported. Mortality within 7 days of bacteremia was 
significantly higher for Gram-negative pathogens (45%) than 
Gram-positive pathogens (13%) (P = .02).
Clostridium difficile was the most common bacterial path-
ogen causing infection. There were 198 episodes of C difficile 
infection (CDI) in 148 patients (33%). Most patients (110 
[74%]) had a single episode, although recurrent CDI developed 
in 38 (26%). The median time to CDI was 27 days posttrans-
plant. Clostridium difficile infection occurred after 118 (37%) of 
319 myeloablative transplants versus 30 (24%) of 125 non-my-
eloablative transplants (odds ratio [OR], 1.6; 95% confidence 
interval [CI], 1.1–2.3). Of the 148 patients with CDI, 93 (63%) 
ultimately died, compared with 138 (47%) of those without 
CDI infection (OR, 1.9; 95% CI, 1.3–2.9). No infections with 
Nocardia or mycobacterial species were identified.
Pneumonia developed in 132 (30%) patients. Of the 75 
episodes in which a pathogen was identified, 38 (51%) were 
bacterial, 26 (35%) were fungal, and 11 (15%) were viral. The 
mortality rate for patients with pneumonia was 62.1% com-
pared with 47.8% for those who never developed pneumonia 
(OR, 1.79; 95% CI, 1.18–2.72). There were 136 symptomatic 
urinary tract infections among 89 (20%) patients. Sinusitis 
occurred in 30 (7%) patients. Only 6 episodes of sinusitis had 
a microbiologic diagnosis: 2 bacterial and 4 fungal (mucorales 
n = 2, Alternaria n = 1).
Viral Infections
Viral infections are displayed in Table 5. Cytomegalovirus was the 
most common viral infection (154 patients, 35%). Most episodes 
were limited to viremia, but organ involvement developed in 6 
(4%) patients including the following: 4 with enteritis, 1 with hep-
atitis, and 1 with pneumonia. Infection with respiratory viruses 
occurred in 49 (11%) patients. Of 18 patients with parainfluenza 
infection, there were 8 episodes of pneumonia or other lower res-
piratory tract infection. Of the 15 patients with influenza infec-
tion, 6 had pneumonia or other lower respiratory tract infection. 
Among 13 patients with respiratory syncytial virus infection, 
there were 6 episodes of pneumonia or other lower respiratory 
tract infection. Of the 6 patients with adenovirus infections, 2 
Table 2. Type of Transplant and Conditioning Regimen in 444 Patients
Characteristic n (%)
Transplant Type
 Matched, unrelated 245 (55)
 Matched, related 177 (40)
 Mismatched, unrelated 20 (5)
 Mismatched, related 2 (1)
 Tandem 8 (2)
Transplant Source
 Peripheral blood 386 (87)
 Bone marrow 53 (12)
 Umbilical cord 5 (1)
 T-cell depleted 2 (<1)
Myeloablative conditioning regimen 319 (72)
Immunosuppressiona
 Tacrolimus 388 (87)
 Cyclosporine 90 (20)
aAt any time posttransplant.
Table  3. Bacterial Bloodstream Infections in 444 Hematopoietic Cell 
Transplant Recipients
Characteristic N (Percent or Range)
Gram positive 244 (56)
Coagulase-negative staphylococci 125 (51)
Vancomycin-resistant Enterococcus 41 (17)




Enterococus faecalis 8 (3)
Methicillin-resistant S aureus 7 (3)
β-hemolytic streptococci 4 (2)
Other 8 (3)
Gram negative 93 (21)
Pseudomonas aeruginosa 24 (26)
Escherichia coli 20 (22)
Klebsiella pneumonia 20 (22)
Stenotrophomonas maltophilia 6 (7)
Citrobacter freundii 5 (5)
Enterobacter cloacae 5 (5)
Acinetobacter baumanii complex 3 (3)
Burkholderia cepacia 2 (2)
Other 8 (9)
Polymicrobialb 50 (12)
aInfection level data (n = 437), some patients had more than 1 infection.
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had disseminated infection, 2 had pneumonia, 1 had viremia, 
and 1 had gastroenteritis. Of the 49 patients with respiratory viral 
infections, 6 (12%) died within 14 days of infection.
Thirteen patients developed VZV infection, 11 of whom 
had dermatomal skin lesions. One patient had disseminated 
disease, and 1 had VZV meningitis. Only 1 of these patients 
was receiving antiviral prophylaxis at the time of VZV 
infection. There were 2 documented cases of viral meningi-
tis: the previously mentioned varicella zoster, and 1 due to 
human-herpesvirus 6.
Fungal Infections
A total of 53 IFI (18 probable and 35 proven) occurred among 
48 (11%) patients (Table 4). The median time to the develop-
ment of IFI was 142 days (range, 14–666). There were 18 infec-
tions caused by yeasts (all candidemias), 32 mold infections, 
and 3 infections with P jiroveci. None of the patients with P 
jiroveci pneumonia were receiving prophylaxis at the time of 
diagnosis. There were no diagnosed cases of cryptococcosis or 
endemic mycoses.
The median time from the diagnosis of IFI to death was 
29 days (0–868), and among the 15 patients with data availa-
ble, 60% died within 6 weeks of diagnosis. The most common 
syndromes were as follows: pneumonia (n  =  25), candidemia 
(n = 18), sinusitis (n = 4), and disseminated infection (n = 4) 
(Table 4). Mucorales infections were uncommon (n = 5). Of the 
16 patients with candidemia, there were no cases of dissemi-
nated infection.
Outcomes
Of the entire cohort of 444 patients, 113 (26%) had relapse of 
their underlying disease during the study period and 231 (52%) 
died (Table 6). The median time from transplant to death was 
167 days (range, 5–885). The cause of death was attributed to 
the underlying disease in 102 (44%) patients, to infection in 
49 (21%), and to other or unknown causes in 35%. Transfer 
to an intensive care unit occurred for 162 (36%) of patients, 
and, of those, 122 (75%) ultimately died. Most patients (86%) 
who required mechanical ventilation did not survive. Dialysis 
occurred in 36 (8%) patients, and 25 (69%) of these patients died.
DISCUSSION
We report results from a large prospective, multicenter study 
that examined all infectious complications after allogeneic HCT. 
Infection is a substantial cause of morbidity and mortality and 
was the second most common cause of death after relapse of 
the underlying malignancy. Our study reveals suggests that sev-
eral interventions have been successful in preventing infection 
after HCT. Only 1% of patients developed a CMV infection with 
organ involvement, likely attributable to antiviral prophylaxis. 
Cytomegalovirus pneumonia, which was a major cause of mor-
tality in the era before prophylaxis or early treatment strategies 
[12], was seen in only 1% of our cohort. Likewise, the frequen-
cies of herpes simplex virus, VZV, and human herpes virus-6 
infections were very low, consistent with effective prophylac-
tic strategies, although it should be noted that routine screen-
ing for these infections was not part of the study and that less 
severe infections may have been missed. Pneumocystis jiroveci 
pneumonia was seen in less than 1% of patients and occurred 
only when prophylaxis was not used. There were no cases of 
Table  4. Proven and Probable Invasive Fungal Infections in 444 
Hematopoietic Cell Transplant Recipientsa









 Pneumonia 26 (49)
 Bloodstream infection 18 (34)
 Sinusitis 4 (8)
 Disseminated 4 (8)
 Central nervous system 1 (2)
aFifty-three infections among 48 patients.
Table 5. Viral Infections in 444 Hematopoietic Cell Transplant Recipients 
(n = 187)
Virus N (%)
Cytomegalovirus infection 154 (82)
 Viremia only 148 (96)
 Organ involvementa 6 (4)
Human herpes virus-6 21 (11)
Parainfluenza virus 18 (10)
Varicella zoster virus 13 (7)
Respiratory syncytial virus 13 (7)
Influenza A virus 12 (6)
Epstein-Barr virus 10 (5)
Herpes simplex virus 8 (4)
Adenovirus 6 (3)
Influenza B virus 3 (2)
aOne hepatitis, 1 pneumonia, 4 enteritis.
Table 6.  Outcomes in 444 Hematopoietic Cell Transplant Recipients
Characteristic n (%)
Median time to engraftment, days 12 (0–101)
Graft-versus-host disease requiring treatment 336 (76)
Death 231 (52)
 Death from underlying disease 102 (44)
 Death from infection 49 (21)
Autopsy performed 24 (5)








niversity in St. Louis user on 26 O
ctober 2019
Infections After Hematopoietic Cell Transplant • OFID • 5
toxoplasmosis, nocardiosis, endemic mycoses, or mycobacterial 
infection diagnosed in our cohort, in agreement with low rates 
of these infections reported previously [13–20].
In contrast to lower frequencies of viral and P jiroveci 
infections observed, the rates of bacteremia remain high. 
Most occurred before engraftment. Consistent with previ-
ous studies, Gram-positive bacteremias were more common 
than Gram-negatives, likely due to the association of Gram-
positive organisms with central venous catheters [21–23]. 
Several recent studies suggest that the ratio of Gram-positive 
to Gram-negative bacteremias has been decreasing [23–25]. 
Pseudomonas aeruginosa remains the most common etiology 
of Gram-negative bloodstream infections despite the standard 
use of anti- pseudomonal β-lactam agents as empiric therapy for 
neutropenic fever. Others have variably reported Escherichia coli 
as the most common Gram-negative pathogen [3, 23, 26–28], 
or Pseudomonas [1, 24]. This finding is particularly concerning 
given that the 7-day mortality from Gram-negative bacteremia 
was approximately 50%, which is more than 3-fold higher than 
for Gram-positive bacteremia. We were not able to analyze anti-
microbial resistance patterns to determine what proportion of 
these infections represented failure of empiric therapy.
The most common bacterial infectious complication was 
C difficile, which occurred in one third of patients. This rate 
is higher than that reported in other inpatient populations. A 
review of US hospital admissions in 2009 found a CDI diagno-
sis in 0.9% of patients [29]. The overall incidence of CDI in the 
United States in 2011 was 7.4 per 10 000 patient days and rep-
resented 12.1% of all healthcare-associated infections [30, 31]. 
Others have similarly reported a higher incidence of CDI in the 
HCT population with incidence rates varying from 4% to 13% 
[32–36]. Clostridium difficile infections most often occurred 
before engraftment, suggesting that neutropenia, more intense 
exposure to antimicrobials and immunosuppression, and trans-
mission in the hospital environment are likely to be important 
risk factors. Another study is underway using this cohort and 
a parallel cohort of lung transplant recipients from OTIP to 
provide more detail on risk factors and outcomes for CDI. The 
association of CDI with GVHD of the gastrointestinal tract has 
been previously reported, and further study is needed in this 
area [32, 36–38].
Respiratory viral infections were more frequent than 
expected, which may be a result of increased access to testing 
in both inpatient and outpatient settings and ease and rapid-
ity of current molecular detection methods. They occurred in 
11% of our cohort, compared with previously reported rates of 
1.8%–4.3% [9, 39, 40]. Approximately half of patients with these 
infections developed pneumonia or disseminated disease. It is 
well known that geographic and seasonal factors are important 
as well as transmission within the hospital environment [4, 5, 
41–47]. Further studies will be important to tease out the effects 
of these factors.
Current antifungal strategies are relatively effective at pre-
venting candidemia, but rates of invasive mold infection remain 
constant [4]. Similar to other reports, the median time to an 
IFI was 142  days, a time when most HCT recipients are out-
patients [4, 5, 45, 48]. Death occurred within 6 weeks of IFI in 
60%, highlighting the need for early diagnosis and improved 
prophylaxis and treatment. There have been several reports of a 
rise in infections with the Mucorales in this population [49–53] 
and an association with the prophylactic use of triazoles such as 
voriconazole, which lack activity against these agents [48, 50]. In 
our cohort, these infections were extremely rare. The difficulty 
in establishing the diagnosis of invasive mold infection in this 
population is well recognized, and it is possible that our rates 
underestimate the true incidence. We found that there were few 
survivors among patients who required mechanical ventilation 
or dialysis after hematopoietic stem cell transplant, in keeping 
with known high mortality rates in patients who require ICU 
admission or have evidence of multiorgan failure [54–57].
Our study has several limitations. We were able to enroll 
only 48% of the transplants that were performed at our centers 
over the study period. Because we did not collect data on 
the nonparticipants, we do not know how representative our 
patients were of the total population. Our study was limited 
by the recognized difficulties in establishing proven infection 
in this population. We did not collect granular data on GVHD 
severity, duration, and treatment. Neutropenia and GVHD 
are well known risk factors for many of the infectious com-
plications after allogeneic HCT. Although we were not able to 
examine these risk factors, we believe that our results provide 
an important snapshot of the incidence of infectious disease 
events after HCT from diverse geographic settings and pro-
spective data collection. In addition, we lacked data on many 
important noninfectious complications that may have influ-
enced the risk for infection. The difficulty in ascertaining the 
cause of death in this population with multiple comorbidities 
and complications is a recognized problem as well. Because we 
lacked detailed data on GVHD, it is possible that some patients 
who died with infection really had GVHD as the cause of 
death. Finally, it should be noted that 95% of our population 
was white, and it is unclear whether rates of infection in our 
centers, which although geographically diverse, are generaliza-
ble to other transplant settings.
CONCLUSIONS
Several important areas for future investigation are highlighted 
by our study. Risk factors for bacteremia and C difficile infec-
tions that occur before engraftment should be examined to 
help inform prophylactic strategies during different stages of 
immune reconstitution post-HCT. Further information on the 
timing and type of environmental exposures that lead to inva-
sive mold infection is needed to prevent these devastating infec-
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state of immunosuppression in an individual patient will allow 
a finer stratification of risk for infection.
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